Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumors

BACKGROUND: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K-AKT-mTOR) signaling pathway is aberrantly activated in several cancers. Notch signaling maintains cell proliferation, growth, and metabolism in part by driving the PI3K pathway. Combining the mTOR inhi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Cancer
Main Authors: Piha-Paul, S.A., Munster, P.N., Hollebecque, A., Argilés, G., Dajani, O., Cheng, J.D., Wang, R., Swift, A., Tosolini, A., Gupta., S.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693226/
https://ncbi.nlm.nih.gov/pubmed/26199039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.06.115
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker